NEW YORK (GenomeWeb) – Researchers from the University of Montreal have developed a proteogenomic approach to identify tumor-specific antigens for use in cancer immunotherapies.

Tumor-specific antigens (TSAs) help the immune system respond to cancer, and cancer immunotherapies may target them to boost that response. But according to Montreal's Claude Perreault and his colleagues, approaches for uncovering TSAs have been beset by false-positive findings or meager yield, and have focused on mutated TSAs rather than aberrantly expressed TSAs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.